Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Mastocytosis, Systemic 4Neoplasm Metastasis 2Systemic Mastocytosis With an Associated Hematologic Neoplasm 1Sarcoma 1Recurrence 1Neoplasm, Residual 1Melanoma 1Mastocytosis 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Mast-Cell 1Glioma 1Gastrointestinal Stromal Tumors 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 8Specimen Handling 7Biopsy 6X-Rays 5Phantoms, Imaging 5Temozolomide 4Nuclear Medicine Department, Hospital 4Nivolumab 4Carboplatin 4selpercatinib 3larotrectinib 3Topotecan 3Etoposide 3Cyclophosphamide 3Cisplatin 3Automobiles 3tazemetostat 2pembrolizumab 2erdafitinib 2entrectinib 2ensartinib 2cabozantinib 2Vincristine 2Surveys and Questionnaires 2Radiotherapy 2Radiosurgery 2Radiation 2Positron-Emission Tomography 2Paclitaxel 2ONC206 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × avapritinib × 1 year × Clear all
NCT04773782 2026-01-13

A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

Blueprint Medicines Corporation

Phase 1/2 Completed
29 enrolled
CNS

Glioma, Recurrence, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡